Abstract Number: 366 • 2019 ACR/ARP Annual Meeting
Serum Uric Acid Level and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals: An Observational Cohort Study
Background/Purpose: High serum uric acid (SUA) level is the main prerequisite for gout, and it might be associated with obesity, hypertension, glucose intolerance, insulin resistance,…Abstract Number: 814 • 2019 ACR/ARP Annual Meeting
Interferon Signature and Cytokine Patterns Define Novel Autoinflammatory Diseases
Background/Purpose: Undifferentiated systemic autoinflammatory diseases (USAID) present diagnostic and therapeutic challenges. Cytokine dysregulation may identify disease groups that respond to targeted treatments. IFN-signaling blocking treatments…Abstract Number: 900 • 2019 ACR/ARP Annual Meeting
Serum Urate Lowering with Allopurinol Improves Endothelial Function in Young Adults
Background/Purpose: An effect of serum urate on vascular endothelium has been postulated as a mechanism for its association with hypertension and cardiovascular disease. Prior studies…Abstract Number: 902 • 2019 ACR/ARP Annual Meeting
The Effects of a Low-Fat, Mediterranean, or Low-Carbohydrate Diet on Serum Urate
Background/Purpose: Gout and hyperuricemia are associated with cardiometabolic comorbidities and increased risk of premature mortality. Often, low-purine (i.e., low-protein) diets are recommended for patients with…Abstract Number: 1113 • 2019 ACR/ARP Annual Meeting
Improving Healthcare Quality and Reducing Cost via Online Interaction for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tool
Background/Purpose: Without efficient primary medical care and follow-up system in China, patients can choose any hospital or doctor they like in seeking medical care. As…Abstract Number: 1155 • 2019 ACR/ARP Annual Meeting
The Status of Latin-American Women in Rheumatology
Background/Purpose: Currently, Latin America does not have detailed information of women in rheumatologists based on education, working conditions, productivity, distribution of time between work activities…Abstract Number: 1168 • 2019 ACR/ARP Annual Meeting
Frequently Encountered Artifacts in Novel Application of Dual-Energy CT to Vascular Imaging: A Pilot Study
Background/Purpose: One hypothesized link between cardiovascular disease and gout is the direct deposition of monosodium urate (MSU) crystals in atherosclerotic plaque. A 2018 ACR abstract…Abstract Number: 1212 • 2019 ACR/ARP Annual Meeting
Psychological Profile in Patients with Rheumatic Diseases in China: A Study of HADS Self-assessment with Smart System of Disease Management (SSDM)
Background/Purpose: The patients with chronic diseases such as rheumatic diseases suffer from physical pain and/or disability. In addition, psychological morbidities have also been found in…Abstract Number: 1213 • 2019 ACR/ARP Annual Meeting
A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology
Background/Purpose: There is lack of appropriate outpatient follow-up (F/U) for hospitalized rheumatology patients, which can result in disease recurrence and recurrent inpatient admissions1. This is…Abstract Number: 1215 • 2019 ACR/ARP Annual Meeting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate Efficacy and Tolerability of SHR4640 in Patients with Hyperuricemia
Background/Purpose: Hyperuricemia, a common metabolic disorder, predisposes patients to develop gout due to the deposition of insoluble urate in joints. Safety concerns are frequently raised…Abstract Number: 1223 • 2019 ACR/ARP Annual Meeting
Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia
Background/Purpose: Uric acid homeostasis is determined as a balance between production, intestinal secretion and renal excretion. Around 2/3 of uric acid is excreted by the…Abstract Number: 1224 • 2019 ACR/ARP Annual Meeting
AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile
Background/Purpose: AR882 is a potent and selective inhibitor of uric acid transporter 1 (URAT1), which is responsible for a majority of reabsorption of filtered uric…Abstract Number: 1229 • 2019 ACR/ARP Annual Meeting
AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial
Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. A Phase 1…Abstract Number: 1234 • 2019 ACR/ARP Annual Meeting
Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is “Normal”?
Background/Purpose: Elevated serum uric acid (UA) concentration is associated with the urate crystal deposition disorders gout and nephrolithiasis, as well as hypertension, the metabolic syndrome,…Abstract Number: 1238 • 2019 ACR/ARP Annual Meeting
Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter
Background/Purpose: Monosodium urate (MSU) andmonoclinic calcium pyrophosphate dihydrated(mCPPD)crystals are responsible for relapsing acute arthritis which is driven by interleukin 1β (IL-1β).IL-1βproductionrelies onNLRP3 inflammasome activationleading to…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »